LRP2 sirna

LRP2 siRNA (Human)

Cat. Num. AAA8235411

• Gene Names: LRP2; DBS; GP330
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: LRP2; LRP2 siRNA (Human); Low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: LRP2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 4655

• Applicable Applications for LRP2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LRP2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for LRP2 sirna

siRNA to inhibit LRP2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 126012573
• NCBI GeneID: 4036
• NCBI Accession #: NP_004516.2
• NCBI GenBank Nucleotide #: NM_004525.2
• UniProt Accession #: P98164; O00711; Q16215
• Molecular Weight: 521,958 Da
• NCBI Official Full Name: low-density lipoprotein receptor-related protein 2
• NCBI Official Synonym Full Names: low density lipoprotein receptor-related protein 2
• NCBI Official Symbol: LRP2
• NCBI Official Synonym Symbols: DBS; GP330
• NCBI Protein Information: low-density lipoprotein receptor-related protein 2
• UniProt Protein Name: Low-density lipoprotein receptor-related protein 2
• Protein Family: LRP2-binding protein
• UniProt Gene Name: LRP2
• UniProt Synonym Gene Names: LRP-2; gp330
• UniProt Entry Name: LRP2_HUMAN

NCBI Description

The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]

Uniprot Description

LRP2: Acts together with cubilin to mediate HDL endocytosis. May participate in regulation of parathyroid- hormone and para-thyroid-hormone-related protein release. Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS); also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Belongs to the LDLR family.

Protein type: Receptor, misc.; Membrane protein, integral; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: Golgi apparatus; endocytic vesicle; lysosome; endoplasmic reticulum; brush border membrane; lysosomal membrane; apical plasma membrane; plasma membrane; integral to membrane; coated pit; endosome; receptor complex

Molecular Function: protein binding; calcium ion binding; SH3 domain binding

Biological Process: steroid metabolic process; phototransduction, visible light; receptor-mediated endocytosis; cell proliferation; forebrain development; protein amino acid glycosylation; endocytosis; lipid metabolic process; retinoid metabolic process; vitamin D metabolic process

Disease: Donnai-barrow Syndrome